BOCA RATON, Fla. , July 28, 2020 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the appointment of Hoi-Bun “Benson” Suen as Vice President of International Sales. Mr. Suen will focus on sales of the Company’s Superficial Radiation Therapy (SRT) products across Southeast Asia and will report directly to Joe Sardano, chief executive officer. The Company is also announcing the resumption of shipments to China with the sale of an SRT-100™ system, a direct result of Mr. Suen’s efforts.Mr. Suen brings to Sensus nearly 20 years of business development, sales and regulatory experience supporting the distribution of U.S. medical devices and other products throughout Asia and in particular China. Most recently, he was Director, Business Development at Fosun Pharma, with responsibility for identifying complementary products to expand the Fosun/Chindex product portfolio and providing strategies for companies to enter the China market. From 2010 to 2016 he was Senior Manager, Business Development and Regulatory at Chindex International, prior to its acquisition by Fosun Pharma. At Chindex, Mr. Suen was part of a team that initiated and managed the first robotic surgery reference center in China, and established one of the most successful da Vinci Surgical System marketing programs in the world. From 2004 to 2010 he served as Manager, Business Development at Prosperity Link in Beijing, where he was responsible for the annual sourcing of more than $50 million in food products from the U.S.“We are delighted to welcome Benson to the Sensus team, where he has had an immediate and positive impact on our sales efforts in China. The SRT-100 system sold and shipped is to be used not only for keloid scars, but also for the treatment of non-melanoma skin cancer,” said Mr. Sardano. “We worked with Benson when he was with our China distributor, and know his abilities first-hand. His knowledge of both distribution into China and China end users will be invaluable. We anticipate several more SRT-100 units will be shipped to China later this year.”“After almost 20 years of working in the Asia market, I am very delighted to be part of the Sensus family, a company that I have known for many years, with a great technology to help people with skin cancer and keloids,” said Mr. Suen. “Both doctors and patients are impressed by the clinical results of the SRT-100. I am confident that with the support of the Sensus team, I will be able to place more systems in the region, where there are great needs to help patients, eliminating their pain both physically and aesthetically. People in that region deserve the best technology.”Mr. Suen holds a B.S. degree from the University of Maryland Smith School of Business, in Management Science and Statistics with a specialization in Decision and Information Sciences.About Sensus HealthcareSensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ modulated robotic brachytherapy radiation oncology system provides targeted directional anisotropic radiation therapy (ART) and brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.For more information, visit www.sensushealthcare.com.Forward-Looking StatementsThis press release includes statements that are, or may be deemed, ‘’forward-looking statements.’’ In some cases these forward-looking statements can be identified by the use of forward-looking terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words.By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and healthcare, regulatory and scientific developments, and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of, among other factors: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing; our ability to achieve and sustain profitability; market acceptance of our product lines; our ability to successfully commercialize our products; our ability to compete effectively in selling our products and services, including responding to technological change and cost containment efforts of our customers; our need and ability to obtain additional financing in the future; our ability to expand, manage and maintain our direct sales and marketing organizations; our ability to obtain and maintain intellectual property of sufficient scope to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products declines; the level and availability of government and third party payor reimbursement for clinical procedures using our products; our ability to effectively manage our anticipated growth, including hiring and retaining qualified personnel; the regulatory requirements applicable to us and our competitors; our ability to manufacture our products to meet demand; our current reliance on third party manufacturers and sole- or single-source suppliers, as well as our ability to successfully transition manufacturing of our products in-house; our ability to reduce the per unit manufacturing costs; our ability to efficiently manage our manufacturing processes; the regulatory and legal risks, and certain operating risks, that our international operations subject us to; the fact that product quality issues or product defects may harm our business; the accuracy of our financial statements and accounting estimates, including allowances for accounts receivable and inventory obsolescence; any product liability claims; new legislation, administrative rules, or executive orders, including those that impact taxes and international trade regulation; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in Sensus Healthcare’s filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release. You should read carefully our “Cautionary Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
Bay Street News